Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Contract Research Organization Market

ID: MRFR/HC/42402-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026
Japan Contract Research Organization Market Research Report By Type Outlook (Drug Discovery, Clinical Development), By Clinical Trial Outlook (Preclinical Trials, Phase I, Phase II, Phase III, Phase IV, Others) and By End User Outlook (Academic institutes, Pharmaceutical companies, Medical service companies) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Service Type (USD Million)
      1. 4.1.1 Clinical Research Services
      2. 4.1.2 Preclinical Services
      3. 4.1.3 Laboratory Services
      4. 4.1.4 Consulting Services
    2. 4.2 Industrial Automation & Equipment, BY Therapeutic Area (USD Million)
      1. 4.2.1 Oncology
      2. 4.2.2 Cardiology
      3. 4.2.3 Neurology
      4. 4.2.4 Infectious Diseases
      5. 4.2.5 Endocrinology
    3. 4.3 Industrial Automation & Equipment, BY End User (USD Million)
      1. 4.3.1 Pharmaceutical Companies
      2. 4.3.2 Biotechnology Companies
      3. 4.3.3 Medical Device Companies
      4. 4.3.4 Academic Institutions
    4. 4.4 Industrial Automation & Equipment, BY Phase of Development (USD Million)
      1. 4.4.1 Preclinical
      2. 4.4.2 Phase I
      3. 4.4.3 Phase II
      4. 4.4.4 Phase III
      5. 4.4.5 Phase IV
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 IQVIA (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Labcorp Drug Development (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PPD (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Charles River Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Syneos Health (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Medpace (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PRA Health Sciences (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Wuxi AppTec (CN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Eurofins Scientific (LU)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 JAPAN MARKET ANALYSIS BY SERVICE TYPE
    3. 6.3 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
    4. 6.4 JAPAN MARKET ANALYSIS BY END USER
    5. 6.5 JAPAN MARKET ANALYSIS BY PHASE OF DEVELOPMENT
    6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SERVICE TYPE, 2024 (% SHARE)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PHASE OF DEVELOPMENT, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PHASE OF DEVELOPMENT, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SERVICE TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
      4. 7.2.4 BY PHASE OF DEVELOPMENT, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Japan Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Service Type (USD Million, 2025-2035)

  • Clinical Research Services
  • Preclinical Services
  • Laboratory Services
  • Consulting Services

Industrial Automation & Equipment By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Endocrinology

Industrial Automation & Equipment By End User (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Academic Institutions

Industrial Automation & Equipment By Phase of Development (USD Million, 2025-2035)

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV